Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Thomas, Langbein"'
Autor:
Benedikt Feuerecker, Andrei Gafita, Thomas Langbein, Robert Tauber, Christof Seidl, Frank Bruchertseifer, Jürgen E. Gschwendt, Wolfgang A. Weber, Calogero D’Alessandria, Alfred Morgenstern, Matthias Eiber
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 23, p 16845 (2023)
Most Prostate Specific Membrane Antigens (PSMAs) targeting small molecules accumulate in the salivary glands (SGs), raising concerns about SG toxicity, especially after repeated therapies or therapy with 225Ac-labeled ligands. SG toxicity is assessed
Externí odkaz:
https://doaj.org/article/8679634db1754150a73ed6bafa3890e2
Autor:
Hui Wang, Thomas Amiel, Christoph Würnschimmel, Thomas Langbein, Katja Steiger, Isabel Rauscher, Thomas Horn, Tobias Maurer, Wolfgang Weber, Hans-Juergen Wester, Karina Knorr, Matthias Eiber
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Background The prostate-specific membrane antigen (PSMA) is a relevant target in prostate cancer, and immunohistochemistry studies showed associations with outcome. PSMA-ligand positron emission tomography (PET) is increasingly used for prim
Externí odkaz:
https://doaj.org/article/6873ede5c122459d8faaa935cb34206f
Autor:
Thomas Langbein, Harshad R. Kulkarni, Christiane Schuchardt, Dirk Mueller, Gerd Fabian Volk, Richard P. Baum
Publikováno v:
Diagnostics, Vol 12, Iss 8, p 1926 (2022)
Purpose: PSMA-targeted radioligand therapy (PRLT) is a promising treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). However, a high uptake of the radiopharmaceutical in the salivary glands (SG) can lead to xer
Externí odkaz:
https://doaj.org/article/b7604289a7394eff80e2be0d2b0d9cf9
Publikováno v:
Toxins, Vol 14, Iss 1, p 64 (2022)
Botulinum Toxin injections into salivary glands (SG) up to a total dose of 100 units IncobotulinumtoxinA (IncoA) represent the treatment of choice for sialorrhea. However, BTX might also protect SG against sialotoxic radioligand cancer therapies. The
Externí odkaz:
https://doaj.org/article/e48e81fc85044017a938c58448e7bfac
Autor:
Thomas Langbein, Hui Wang, Isabel Rauscher, Markus Kroenke, Karina Knorr, Alexander Wurzer, Kristina Schwamborn, Tobias Maurer, Thomas Horn, Bernhard Haller, Hans-Jürgen Wester, Matthias Eiber
Publikováno v:
Journal of Nuclear Medicine. 63:1334-1342
Publikováno v:
Der Radiologe. 61:818-824
Das Prostatakarzinom ist die haufigste maligne Erkrankung und die zweithaufigste karzinombedingte Todesursache bei Mannern in Deutschland. Eine sichere Diagnose und ein Staging mit praziser Bildgebung sind entscheidend, um den Patienten eine zielgena
Autor:
Lukas, Lunger, Maythinee, Chantadisai, Amir, Karimzadeh, Isabel, Rauscher, Calogero, D'Alessandria, Benedikt, Feuerecker, Thomas, Langbein, Robert, Tauber, Stefan, Schiele, Wolfgang Andreas, Weber, Matthias, Eiber
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
To assess the prognostic utility of conventional biochemical and imaging response criteria and
Autor:
Matthias Eiber, Thomas Langbein
Publikováno v:
Radiopraxis. 14:E25-E38
In den letzten Jahren hat die PSMA-Liganden-PET vielversprechende Ergebnisse gezeigt und so enorm an Bedeutung bei der Versorgung von Prostatakarzinompatienten gewonnen. Dieser Beitrag soll einen Überblick zur PSMA-PET/CT in unterschiedlichen klinis
Autor:
Hans-Jürgen Wester, Alexander Wurzer, Wolfgang A. Weber, So Won Oh, Thomas Langbein, Eugene J. Teoh, Sohee Oh, Saskia Kropf, Matthias Eiber, Michael Herz, Markus Krönke
Publikováno v:
Journal of Nuclear Medicine. 61:702-709
Radiohybrid PSMA (rhPSMA) ligands, a new class of theranostic prostate-specific membrane antigen (PSMA)-targeting agents, feature fast 18F synthesis and utility for labeling with radiometals. Here, we assessed the biodistribution and image quality of
Publikováno v:
Toxins
Toxins; Volume 14; Issue 1; Pages: 64
Toxins, Vol 14, Iss 64, p 64 (2022)
Toxins; Volume 14; Issue 1; Pages: 64
Toxins, Vol 14, Iss 64, p 64 (2022)
Botulinum Toxin injections into salivary glands (SG) up to a total dose of 100 units IncobotulinumtoxinA (IncoA) represent the treatment of choice for sialorrhea. However, BTX might also protect SG against sialotoxic radioligand cancer therapies. The